Logo

enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

Share this

enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

Shots:

  • The P-I/II (LEGEND) dose-escalation trial evaluated safety and tolerability, PK, PD & efficacy of EG-70 in patients with BCG-unresponsive high-grade NMIBC with CIS
  • The results showed that 83% of patients achieved CR @3mos., no DLTs or SAEs were observed, AEs were limited to transient Grade 1 & 2. The therapy was safe & well-tolerated with promising clinical efficacy in high-grade NMIBC patients with CIS in whom BCG has failed
  • EG-70 is a non-viral gene therapy encoding 2 RIG-I agonists that stimulate the innate immune system & IL-12 stimulates the adaptive immune system. The therapy showed the tumor regression in preclinical models of bladder cancer

Ref: PR Newswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions